11th European Conference on Clinical Neuroimaging March 2023 Genoa , Italy


Barthel Henryk

"Is there a future for the new brain dedicated PET systems?" - March 14, 2022 at 10.15am
Henryk Barthel, MD, is Professor and Assistant Medical Director of the Department of Nuclear Medicine of the University Hospital Leipzig (Germany). He underwent training in Nuclear Medicine in Heidelberg (Germany) and Leipzig. From 2000 to 2003 he was as a Research Fellow at the Imperial College Hammersmith Hospital in London (UK). Dr. Barthel’s current research activities focus on new PET imaging techniques to improve diagnosis and treatment of neurodegenerative and cerebrovascular diseases, as well as on hybrid brain PET/MR imaging. To support the general progress of nuclear brain imaging, he serves as Vice-Chair of the Neuroimaging Committee of the European Association of Nuclear Medicine (EANM), EANM Representative to the European Academy of Neurology, and Associate Editor of The Journal of Nuclear Medicine.

Blennow Kaj

"Plasma screening: a game changer for diagnostic algorithms" - March 14, 2022  at 2.15pm
Kaj Blennow is Professor and Academic Chair in Clinical Neurochemistry at University of Gothenburg, and Head of the Clinical Neurochemistry Lab at Sahlgrenska University Hospital, Gothenburg, Sweden. He has published more than 1600 original research papers and review articles in peer-reviewed journals, with more than 106.000 citations, and he has an H-index of 150.
His main research interest in fluid biomarkers for Alzheimer’s disease (AD) and other brain disorders, and the application of these to increase the understanding of AD pathophysiology, as well as for screening, diagnostics and in therapy monitoring in trials. He is President of the Society for CSF analysis and Clinical Neurochemistry and head of the Alzheimer’s Association QC program for CSF biomarkers.


"Technological developments in PET design: whole body and dedicated systems" - March 14, 2022 at 9.30am

Prof.dr. Ronald Boellaard (M) is appointed as full professor at the Amsterdam University Medical Centers and at the University Medical Center Groningen, The Netherlands. He has a background in biology (MSc) and physics (MSc) and a PhD in science. His research focuses on (pharmacokinetic) quantitative analysis of positron emission tomography (PET), PET image reconstruction and processing. He is member of several international societies and committees (e.g. QIBA technical FDG PET/CT and Amyloid committees, member of EANM NeuroImaging  committee, EORTC imaging workgroup, EARL steering board). He is the principal author for the Netherlands and the European guidelines for standardisation of quantitative FDG PET and PET/CT studies (EJNMMI 2010 & 2015). Specialties: quantitative analysis of positron emission tomography studies; image processing, radiomics and artificial intelligence, image reconstruction, pharmacokinetic analysis (brain, onco, cardio),  PET standardization and QA and more recently Total Body PET/CT.


"The added value of quantification for amyloid PET imaging" - March 14, 2022 at 2.15pm
Andrea Chincarini, PhD, physicist and researcher at the National Institute of Nuclear Physics, after a five-year post-graduate period in Germany and the United States, has been carrying out research in the field of gravitational wave detectors since the 2000s.
He mainly deals with mathematical models, data analysis, artificial intelligence and statistics applied in various fields of experimental physics which include, among other things, significant research in the field of neuroscience and medical physics.
He is currently local manager and member of the VIRGO Scientific Committee of the INFN VIRGO experiment, coordinator of the fifth National Scientific Commission and lecturer of the Gravitational Waves course (Master's degree curriculum in Physics) and at the School of Specialization in Medical Physics of the University of Studies of Genoa. He has been responsible for numerous Italian and European research projects and is a member of various scientific societies.
After earning a second doctorate - in Neuroscience - he founded a research group dedicated to the search for biomarkers in nuclear neurological imaging for the early and differential diagnosis of neurodegenerative diseases.
He is the author of more than 300 publications including works in international journals, monographs and books.



Ferreira Daniel

"PET in Dementia with Lewy Bodies: new insights" - March 15, 2022 at 9.45am
Dr. Daniel Ferreira (https://staff.ki.se/people/daniel-ferreira-padilla) is an associate professor at the Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society (Karolinska Institutet, Sweden). He is also a research affiliate at the Department of Radiology (Mayo Clinic, USA). Dr. Ferreira is currently the Director of Center for Alzheimer Research at Karolinska Institutet (https://ki.se/en/nvs/center-for-alzheimer-research), a hub for all Alzheimer, Dementia, and Aging research at Karolinska Institutet. Dr. Ferreira is principal investigator and head of the MRI Hub for the European-DLB consortium (https://www.e-dlb.com/). He is also the leader of the Swedish DLB Network, as well as member of the emerging Nordic DLB Network. Dr. Ferreira is active member of the ISTAART PIA in Lewy Body Dementias, and is leading a global collaboration between European DLB and Mayo Clinic DLB consortia, with a focus on imaging biomarkers. Main research focus of Dr. Ferreira is neuroimaging and cognition in aging and neurodegenerative dementias. He has made relevant scientific contributions to the fields of biological subtypes of Alzheimer’s disease, neuroimaging in dementia with Lewy bodies, in-vivo modelling of human cholinergic system, cognitive reserve and subjective cognitive decline.


"Elaborating a diagnostic algorithm : an intersocietal consensus" - March 15, 2022 at 11.45am
Pr. Valentina Garibotto is division chair of nuclear medicine and molecular imaging at the University Hospitals of Geneva and associate professor at the Geneva University. Her clinical and research experience focuses on imaging molecular targets, with a specific interest in neurodegenerative diseases.
Pr. Garibotto obtained her doctorate in medicine from the Genoa University Hospital in 2003, her specialization in nuclear medicine at the San Raffaele Hospital and Bicocca University in Milan in 2007 and the title of Privat Docent from the Geneva University in 2014. She has authored more than 190 peer reviewed articles (H index: 31, Scopus 18.11.2021) in the fields of clinical neuroimaging and nuclear medicine.
Her research group works on molecular imaging of neurodegenerative diseases, namely to characterize causative and protecting factors and to support the development of novel therapeutic approaches (
https://www.unige.ch/medecine/radio/en/groupes-de-recherche/984garibotto/ ). These research projects are mainly funded by the Swiss National Research foundation, the Velux Stiftung, the Schmidheiny and Aetas foundation.
She is Congress Chair Elected of the European Association of Nuclear Medicine, Chair of the Neuroimaging group of the Swiss Society of Nuclear Medicine and actively involved in a number of European initiatives fostering molecular imaging of cognitive disturbances, such as the European Alzheimer Disease Consortium PET, the European-Dementia with Lewy Body study group and the AMYPAD initiative.
She’s teaching molecular imaging at the pregraduate and postgraduate level in national and international courses.



"Long COVID: PET demonstrated the brain dysfunctions" - March 15, 2022 at 8.45am
Eric GUEDJ is Professor of Biophysics and Nuclear Medicine at Aix-Marseille University, and head of the Department of Nuclear Medicine of Marseille University Hospital.
He leads the scientific team IMOTHEP at Fresnel Institute (Aix-Marseille University, CNRS, Ecole Centrale) on the topic of biomarkers and theranostics for brain diseases.
Eric GUEDJ is the coordinator of the group of nuclear physicians specialized in brain PET/SPECT imaging at the French National Society of Nuclear Medicine.
He is a member of the Neuroimaging Committee at the European Association of Nuclear Medicine.




"PSMA theranostic for brain tumors: there is a world beyond the prostate" - March 14, 2022 at 1.45pm
Prof. Jolanta Kunikowska is a nuclear medicine as well as internal medicine physician specialist. She is currently professor at the Nuclear Medicine Department, Medical University, Warsaw/Poland. She has a broad interest in positron emission tomography (PET), molecular imaging applications in oncology and theragnostics (radionuclide therapy).  She has a particular interest in novel PET radiotracers, and theragnostic applications including prostate, neuroendocrine tumors and glioblastoma. She has authored over 100 peer-reviewed articles and several book chapters. She received several prestigious awards provided by various scientific communities including the Gold prize for Hisada award in 2018 and Marie Curie Award for outstanding scientific work presented at the 29th Annual Congress of the European Association of Nuclear Medicine (EANM) in Barcelona in 2016. She is currently a President of the EANM.



"Total body PET/CT for the brain: what makes sense? " - March 14, 2022 at 10am
Ian Law is Professor at the University of Copenhagen, Denmark, and Chief Physician at the Dept of clinical physiology, nuclear medicine and PET, Rigshospitalet. He has written his Ph.D and habilitation thesis (DMSc) in PET perfusion imaging. Presently his primary research interests are clinical implementation and research use of PET/CT, PET/MRI, total body PET/CT with focus on neurooncology, neurodegeneration, and cerebrovascular disese.



Tatjana Traub-Weidinger: Associate Professor of Nuclear Medicine, Divisional Head Neuronuclear Medicine, Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Austria.

van Berckel Bart

"COVID and neuroinflammation: the PET studies" - March 15, 2022 at 9.15am
Prof. dr. Bart N.M. van Berckel is appointed as professor of Molecular Brain Imaging at the Amsterdam University Medical Centers in the Netherlands since 2015. He received his MD from the University of Utrecht in 1993 and subsequently obtained his PhD in 1998 at this University. Since 2002, he works as a Nuclear Medicine Physician at the Amsterdam University Medical Centers location VU Medical Center. 
Prof. van Berckel’s research interests focusses on quantitative molecular imaging in Alzheimer’s disease and dementia, as well as neuroinflammation imaging. He participates and/or has an advisory role in many commercial and academic brain imaging studies of the department of Radiology and Nuclear medicine at the VUmc. He (co)authored >230 papers and several book chapters. He is a member of the Neuroimaging Committee at the European Association of Nuclear Medicine


van de Giessen Elsmarieke

​"Blood brain barrier and medication delivery: how PET could help evaluate different strategies for enhanced delivery" - March 15, 2022 at 11.45am

2008 - Medical Degree
2012 - PhD Degree (cum laude) - Imaging of the dopamine and serotonin system in obesity, Academic Medical Center, Amsterdam (Netherlands)
2012-2014 - Post-doctoral research fellow, Imaging of the dopamine system in schizophrenia and substance abuse, Columbia University Medical Center, New York State Psychiatric Institute, New York (USA)
2014 – 2020 - Resident in Radiology and Nuclear Medicine/Research fellow, Academic Medical Center, Amsterdam (Netherlands)
2015 – 2021 - Member EANM Neuroimaging Committee
2020 – present    Staff Radiologist (specialized in nuclear medicine and neuroradiology), Amsterdam UMC, Amsterdam (Netherlands)
Dopamine imaging (PET, SPECT, MRI), Neuropsychiatric disorders (schizophrenia, movement disorders)
Movement Disorders, Dementia, Brain tumors

               Share Share

News | general information | Archives | Press Presse | Newsletters | DOCUMENTS